By SPC News Staff
The FDA today approved avatrombopag (Doptelet, Dova Pharmaceuticals) to treat thrombocytopenia in adults with chronic liver disease (CLD) who are scheduled to undergo a medical or dental procedure.
This is the first thrombopoietin (TPO) receptor agonist approved for this use in the United States. Avatrombopag is designed to mimic the affects of TPO, the primary regulator of normal platelet production.
The safety and efficacy of avatrombopag were studied in two randomized,